Sandoz And Liquidia Triumph On Treprostinil
Court Finds Pair Suffered Losses Of More Than $137m From United Therapeutics Block
Sandoz and partner Liquidia have welcomed a US court decision which found that interference by United Therapeutics with the launch of their generic treprostinil injection rival to Remodulin caused the pair losses of more than $137m.
